New Pharmacological Treatment Approaches for Schizophrenia: Navigating the Post-iclepertin Landscape.

CNS Drugs · 2026 · PMC12909381 · PMID 41609993

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Specifically, in EMPOWER-1 ( n = 379), placebo demonstrated a 13.5-point PANSS improvement (95% CI: − 17.0, − 10.0), while emraclidine 10 mg achieved − 14.7 points and 30 mg achieved − 16.5 points—differences that failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.